5797 studies found for:    "Lymphatic Diseases"
Show Display Options
Rank Status Study
1 Enrolling by invitation Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic Disorders
Conditions: Lymphedema;   Lymphatic Disorders;   Lipedema;   Vascular Malformation;   Vascular Anomaly
Intervention: Drug: NIRFLI with ICG
2 Recruiting National Lymphatic Disease and Lymphedema Registry
Condition: Lymphedema
Intervention:
3 Completed Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome
Conditions: Autoimmune Disease;   Lymphatic Disease;   Lymphoproliferative Disorder
Intervention: Drug: Pyrimethamine
4 Completed A Study of Isoprinosine in Patients With Lymph Node Disease
Conditions: Lymphatic Disease;   HIV Infections
Intervention: Drug: Inosine pranobex
5 Completed The Safety and Effectiveness of Isoprinosine in Patients With Weakened Immune Systems and Lymph Node Disease
Conditions: Lymphatic Disease;   HIV Infections
Intervention: Drug: Inosine pranobex
6 Completed A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Immunodepressed Patients With Uncomplicated Generalized Lymphadenopathy
Conditions: Lymphatic Disease;   HIV Infections
Intervention: Drug: Inosine pranobex
7 Completed The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III)
Conditions: Lymphatic Disease;   HIV Infections
Intervention: Drug: Zidovudine
8 Enrolling by invitation Imaging of Lymphatic Anomalies
Conditions: Gorham Disease;   Lymphatic Diseases;   Lymphangiomatosis
Interventions: Other: Dynamic Contrast Enhanced Magnetic Resonance Lymphangiography (DCMRL);   Other: Heavy Weighted T2 Imaging (T2W);   Other: Lymph Node Access
9 Recruiting Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
Conditions: Lymphoma;   Lymphoma, Non-Hodgkin;   Immune System Diseases;   Immunoproliferative Disorders;   Lymphatic Diseases;   Lymphoproliferative Disorders;   Neoplasms;   Neoplasms by Histologic Type
Intervention: Biological: ATLCAR.CD30 cells
10 Not yet recruiting Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.
Condition: Lymphatic Diseases
Interventions: Drug: Obinutuzumab;   Drug: Ibrutinib;   Drug: CHOP
11 Recruiting Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
Conditions: Hodgkin Disease;   Lymphoma;   Lymphoma, Non-Hodgkin;   Immune System Diseases;   Immunoproliferative Disorders;   Lymphatic Diseases;   Lymphoproliferative Disorders;   Neoplasms;   Neoplasms by Histologic Type
Intervention: Drug: ATLCAR.CD30 cells
12 Recruiting A Phase II Study With Bendamustine Plus Brentuximab Vedotin in Hodgkin's Lymphoma and CD30+ Peripheral T-cell Lymphoma in First Salvage Setting: the BBV Regimen
Condition: Lymphatic Diseases
Interventions: Drug: Brentuximab Vedotin;   Drug: Bendamustine
13 Active, not recruiting Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients
Condition: Lymphatic Diseases
Intervention: Drug: Brentuximab Vedotin
14 Recruiting Sildenafil for the Treatment of Lymphatic Malformations
Conditions: Lymphatic Malformations;   Lymphatic Diseases
Interventions: Drug: Sildenafil 20 mg tablets;   Other: Placebo tablets (resembling Revatio)
15 Recruiting Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
Conditions: Lymphatic Diseases;   Hematopoietic Malignancy
Intervention: Biological: Umbilical Cord Blood (UCB)
16 Recruiting Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders
Conditions: Lymphangiomatosis;   Lymphedema;   Lymphangiectasia;   Pulmonary Lymphangiectasia
Intervention:
17 Completed
Has Results
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
Condition: Hodgkin Lymphoma
Intervention: Drug: Everolimus (RAD001)
18 Recruiting A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia
Conditions: Lymphoma;   Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: Drug: Durvalumab;   Drug: Lenalidomide;   Drug: Rituximab;   Drug: Ibrutinib;   Drug: Bendamustine
19 Not yet recruiting Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-05)
Condition: Relapsed, Diffuse Large B-cell Lymphoma
Intervention: Drug: Betalutin
20 Not yet recruiting Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)
Condition: Non-Hodgkin Lymphoma
Interventions: Drug: Betalutin with HH1 pre-dosing;   Drug: Betalutin with Rituximab pre-dosing

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years